Mina Suh

Mina Suh

Auto-generated profile, based on publicly available information

Mina Suh

EpidStrategies (a Division of ToxStrategies LLC)

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMina Suh
Mina Suh
NMNaimisha Movva
Naimisha Movva
XJXiaohui Jiang
Xiaohui Jiang
LBLauren C Bylsma
Lauren C Bylsma
HRHeidi Reichert
Heidi Reichert
CNChristopher B Nelson
Christopher B Nelson
Background: This study describes leading causes of hospitalization, including respiratory syncytial virus (RSV), in United States infants (10% of total infant hospitalizations from December through March, reaching >15% in January–February. From 2009 through 2011, acute bronchiolitis due to RSV was the leading primary diagnosis in every birth month. Acute bronchiolitis due to RSV was the leading cause among all races/ethnicities, except Asian/Pacific Islanders, and all insurance payer groups. KID analyses confirmed these results. Conclusions: Acute bronchiolitis due to RSV is the leading cause of US infant hospitalizations.

1 November 2014 in Toxicology
Verified
Journal Article
Closed access
DPDeborah M. Proctor
Deborah M. Proctor
MSMina Suh
Mina Suh
SCSharan L. Campleman
Sharan L. Campleman
CTChad M. Thompson
Chad M. Thompson

7 February 2019 in Critical Reviews in Toxicology
Verified
Journal Article
Open access
MSMina Suh
Mina Suh
DWDaniele Wikoff
Daniele Wikoff
LLLoren Lipworth
Loren Lipworth
MGMichael Goodman
Michael Goodman
SFSeneca Fitch
Seneca Fitch
DPDeborah Proctor
Deborah Proctor
Hexavalent chromium [Cr(VI)] is known to cause lung cancer in workers of certain industries, but an association with stomach cancer is uncertain and widely debated. Systematic review and meta-analyses were conducted to assess the risk of stomach cancer mortality/morbidity in humans and experimental animals exposed to Cr(VI). In accordance with the protocol (PROSPERO #CRD4201605162), searches in PubMed and Embase®, and reviews of secondary literature bibliographies, were used to identify eligible studies. Critical appraisal of internal validity and qualitative integration were carried out using the National Toxicology Program’s Office of Health Assessment and Translation (OHAT) approach; meta-analyses were conducted based on the occupational data (the only data suitable for quantitative assessment). Forty-seven publications (3 animal, 44 occupational, 0 non-occupational) met the eligibility criteria. Stomach cancer was only observed in one high risk of bias animal study, and in the low risk of bias studies no stomach cancer was observed. Thus, confidence in this evidence base is high. Environmental epidemiology studies did not meet eligibility criteria because exposure and outcome were not measured at the individual level. Meta-analyses of human data resulted in overall meta relative risks of 1.08 (95% CI: 0.96–1.21) including all studies and 1.03 (95%CI: 0.84–1.26) excluding studies associated with the highest risk of bias. Because most occupational studies have high risk of bias for confounding and exposure domains, the overall confidence in this evidence base is low to moderate. Combining the streams of evidence per the OHAT approach, Cr(VI) does not pose a stomach cancer hazard in humans.

1 June 2018 in Toxicology
Verified
Journal Article
Open access
MSMina Suh
Mina Suh
DPDeborah Proctor
Deborah Proctor
GCGrace Chappell
Grace Chappell
JRJulia Rager
Julia Rager
CTChad Thompson
Chad Thompson
KWKarin Wiench
Karin Wiench
Lower alkyl acrylate monomers include methyl-, ethyl-, n-butyl-, and 2-ethylhexyl acrylate. These acrylates are used in the manufacture of acrylic polymers and copolymers for plastics, food packaging, adhesives, and cosmetic formulations. Although there is limited potential for human environmental exposure, occupational exposure can occur via inhalation and dermal contact. Recently, new genotoxicity data have been generated, along with in silico and in vitro read-cross analyses, for these acrylates. The availability of high-throughput screening (HTS) data through the ToxCast™/Tox21 databases allows for consideration of computational toxicology and organization of these data according to the ten key characteristics of carcinogens. Therefore, we conducted a comprehensive review to evaluate the mechanistic, toxicokinetic, animal, and human data, including HTS data, for characterizing the potential carcinogenicity, mutagenicity, and genotoxicity of these acrylates. Toxicokinetic data demonstrate that these acrylates are metabolized rapidly by carboxylesterase hydrolysis and conjugation with glutathione. HTS data demonstrated an overall lack of bioactivity in cancer-related pathways. Overall, the genotoxicity and mutagenicity data support a cytotoxic, non-genotoxic mechanism for these acrylates. Cancer bioassay studies conducted by the oral, dermal, and inhalation routes in animal models with these acrylates did not show any increase in tumor incidence, with two exceptions. At high doses, and secondary to chronic site-of-contact irritation and corrosion, rodent forestomach tumors were induced by oral gavage dosing with ethyl acrylate, and skin tumors were observed following chronic dermal dosing with 2-ethylhexyl acrylate in C3H/HeJ inbred mice (a strain with deficiencies in wound healing), but not in the outbred NMRI strain. For both dermal and forestomach cancers, tumorigenesis is secondary to high doses and long-term tissue damage, shown to be reversible. With evidence that these chemicals are not genotoxic, and that they cause forestomach and dermal tumors through chronic irritation and regenerative proliferation mechanisms, these acrylates are unlikely to pose a human cancer hazard.

15 August 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMina Suh
Mina Suh
NMNaimisha Movva
Naimisha Movva
XJXiaohui Jiang
Xiaohui Jiang
HRHeidi Reichert
Heidi Reichert
LBLauren C Bylsma
Lauren C Bylsma
CNChristopher B Nelson
Christopher B Nelson
Respiratory syncytial virus (RSV) is the leading cause of hospitalizations in United States infants aged <1 year, but research has focused on select populations. National (Nationwide) Inpatient Sample and National Emergency Department (ED) Sample data (2011–2019) were used to report RSV hospitalization (RSVH), bronchiolitis hospitalization (BH), and ED visit counts, percentage of total hospitalizations/visits, and rates per 1000 live births along with inpatient mortality, mechanical ventilation (MV), and total charges (2020 US dollars). Average annual RSVH and RSV ED visits were 56 927 (range, 43 845–66 155) and 131 999 (range, 89 809–177 680), respectively. RSVH rates remained constant over time (P = .5), whereas ED visit rates increased (P = .004). From 2011 through 2019, Medicaid infants had the highest average rates (RSVH: 22.3 [95% confidence interval {CI}, 21.5–23.1] per 1000; ED visits: 55.9 [95% CI, 52.4–59.4] per 1000) compared to infants with private or other/unknown insurance (RSVH: P < .0001; ED visits: P < .0001). From 2011 through 2019, for all races and ethnicities, Medicaid infants had higher average RSVH rates (up to 7 times) compared to infants with private or other/unknown insurance. RSVH mortality remained constant over time (P = .8), whereas MV use (2019: 13% of RSVH, P < .0001) and mean charge during hospitalization (2019: $21 513, P < .0001) increased. Bronchiolitis patterns were similar. This study highlights the importance of ensuring access to RSV preventive measures for all infants.

16 April 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
HRHeidi Reichert
Heidi Reichert
MSMina Suh
Mina Suh
XJXiaohui Jiang
Xiaohui Jiang
NMNaimisha Movva
Naimisha Movva
LBLauren C Bylsma
Lauren C Bylsma
CNChristopher B Nelson
Christopher B Nelson
Infant mortality due to respiratory syncytial virus (RSV) in the United States is not well understood. From 1999 to 2018, RSV, bronchiolitis, and influenza deaths were described for infants <1 year using linked birth/death datasets from the National Vital Statistics System. Mortality was described overall and by infant birth and death characteristics. Bronchiolitis was included as the plausible upper limit of RSV, while influenza served as a comparator. Total infant deaths were 561 RSV, 1603 bronchiolitis, and 504 influenza, and rates were 6.9 (95% confidence interval [CI], 6.4–7.5), 19.8 (95% CI, 18.9–20.8), and 6.2 (95% CI, 5.7–6.8) per 1 000 000 live births, respectively. The highest RSV rates were observed among <29 weeks’ gestational age infants (103.5; 95% CI, 81.8–129.1), American Indian/Alaskan Native (20.3; 95% CI, 11.6–33.0), and Medicaid-insured (7.3; 95% CI, 5.9–8.9). However, RSV mortality burden was greatest in full-term (53.7%), white (44.9%), and Medicaid-insured (61.7%) infants. Deaths outside the inpatient setting were 21% and 54% for RSV and bronchiolitis; more Medicaid- (58%) and other/unknown-insured (69%) infants with bronchiolitis died outside of the inpatient setting, compared to privately insured infants (48%) (P = .0327). These national estimates emphasize the importance of considering all infants across all healthcare settings when describing RSV mortality.